This is a prospective, randomised, double blind, placebo controlled, parallel arm, cross-over, multicentre study conducted in a population of children and adults with abdominal symptoms observed at outpatient primary health care centres.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
105
2 sachet/day, 21 days, oral
2 sachet/day, 21 days, oral
NZOZ Promed
Kielce, Poland
Świętokrzyskie Centrum Pediatrii - Poradnia Gastroenterologiczna dla Dzieci
Kielce, Poland
Świętokrzyskie Centrum Pediatrii
Kielce, Poland
Prywatna Specjalistyczna Praktyka Lekarska, dr n. med. Małgorzata Sawicka-Parobczyk
Pruszków, Poland
MYCOBIOTIC® influence for the intensity of abdominal pain;
to assess if administration of MYCOBIOTIC® have influence to the intensity of the abdominal symptoms reported by parents or caregivers in questionaire- abdominal pain;
Time frame: Day 21+/-3; Day 42+/-3, Day 49 +/-3
MYCOBIOTIC® influence for the intensity of stool frequency and consistency
to assess if administration of MYCOBIOTIC® have influence to the intensity of the abdominal symptoms reported by parents or caregivers in questionaire- stool frequency and consistency
Time frame: Day 21+/-3; Day 42+/-3, Day 49 +/-3
MYCOBIOTIC® influence for the intensity of abdominal distention
to assess if administration of MYCOBIOTIC® have influence to the intensity of the abdominal symptoms reported by parents or caregivers in questionaire- abdominal distention
Time frame: Day 21+/-3; Day 42+/-3, Day 49 +/-3
MYCOBIOTIC® influence for the intensity of vomiting
to assess if administration of MYCOBIOTIC® have influence to the intensity of the abdominal symptoms reported by parents or caregivers in questionaire- vomiting
Time frame: Day 21+/-3; Day 42+/-3, Day 49 +/-3
MYCOBIOTIC® influence for the intensity of abdominal bloating
to assess if administration of MYCOBIOTIC® have influence to the intensity of the abdominal symptoms reported by parents or caregivers in questionaire- abdominal bloating
Time frame: Day 21+/-3; Day 42+/-3, Day 49 +/-3
Reducuction of the rate of patients with stool culture positive for Candida sp.
to assess whether administration of MYCOBIOTIC® reduces the rate of patients with stool culture positive for Candida sp. in children.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Nowe Zdrowie - CK
Staszów, Poland
Centrum dr Ozimek
Warsaw, Poland
Time frame: Day 42 +/-6